Top Qs
Timeline
Chat
Perspective
DragonFLY
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
DragonFLY, also known as DFLY or H-DFLY, is a serotonin receptor agonist of the phenethylamine, DOx, and FLY families.[1][2] It is the "dragonFLY" (benzodifuran) analogue of 2,5-dimethoxyamphetamine (2,5-DMA or DOH).[1][2]
Remove ads
Pharmacology
The enantiomers of DFLY, (R)-DFLY and (S)-DFLY, show affinity and activity at the serotonin 5-HT2 receptors.[1][2] At the serotonin 5-HT2A receptor, the affinity (Ki) of (R)-DFLY was 1.5 nM and of (S)-DFLY was 37.9 nM, while at the serotonin 5-HT2C receptor, the affinity (Ki) of (R)-DFLY was 0.79 nM and of (S)-DFLY was 6.0 nM.[2] In terms of activational potency at the serotonin 5-HT2A receptor, the EC50 (Emax) of (R)-DFLY was 590 nM (76%) while that of (S)-DFLY was 650 nM (68%).[2] The enantiomers of DFLY have far greater activity as serotonin 5-HT2A receptor agonists than (R)-2,5-DMA but show dramatically lower potency than 4-substituted FLY analogues like Bromo-DragonFLY.[2]
DFLY was included and described as an entry in Alexander Shulgin's 2011 book The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds.[1] However, it is not known to have been assessed in animals or humans, and hence it is unknown whether DFLY has psychedelic or other psychoactive effects in humans.[1]
Remove ads
History
DFLY was first described in the scientific literature by at least 1999.[1][2][3] It was not an explicitly controlled substance in the United States as of 2011.[1]
See also
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads